IL149147A0 - Use of oxcarbazepine for the manufacture of oral dosage form medicament - Google Patents

Use of oxcarbazepine for the manufacture of oral dosage form medicament

Info

Publication number
IL149147A0
IL149147A0 IL14914700A IL14914700A IL149147A0 IL 149147 A0 IL149147 A0 IL 149147A0 IL 14914700 A IL14914700 A IL 14914700A IL 14914700 A IL14914700 A IL 14914700A IL 149147 A0 IL149147 A0 IL 149147A0
Authority
IL
Israel
Prior art keywords
oxcarbazepine
oral dosage
manufacture
dosage form
form medicament
Prior art date
Application number
IL14914700A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL149147A0 publication Critical patent/IL149147A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL14914700A 1999-11-02 2000-10-31 Use of oxcarbazepine for the manufacture of oral dosage form medicament IL149147A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925962.4A GB9925962D0 (en) 1999-11-02 1999-11-02 Organic compounds
PCT/EP2000/010764 WO2001032183A2 (en) 1999-11-02 2000-10-31 Pharmaceutical compositions comprising oxcarbazepine

Publications (1)

Publication Number Publication Date
IL149147A0 true IL149147A0 (en) 2003-01-12

Family

ID=10863836

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14914700A IL149147A0 (en) 1999-11-02 2000-10-31 Use of oxcarbazepine for the manufacture of oral dosage form medicament
IL149147A IL149147A (en) 1999-11-02 2002-04-15 Use of oxcarbazepine in the manufacture of drugs for the treatment of seizures
IL205504A IL205504A0 (en) 1999-11-02 2010-05-03 Pharmaceutical compositions

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL149147A IL149147A (en) 1999-11-02 2002-04-15 Use of oxcarbazepine in the manufacture of drugs for the treatment of seizures
IL205504A IL205504A0 (en) 1999-11-02 2010-05-03 Pharmaceutical compositions

Country Status (25)

Country Link
US (3) US20060079502A1 (zh)
EP (1) EP1242091B1 (zh)
JP (3) JP2003514780A (zh)
KR (1) KR100493836B1 (zh)
CN (1) CN1407894A (zh)
AT (1) ATE401892T1 (zh)
AU (1) AU777705B2 (zh)
BR (1) BR0015188A (zh)
CA (1) CA2388609C (zh)
CZ (1) CZ302847B6 (zh)
DE (1) DE60039629D1 (zh)
ES (1) ES2311001T3 (zh)
GB (1) GB9925962D0 (zh)
HK (1) HK1050839B (zh)
HU (1) HU227685B1 (zh)
IL (3) IL149147A0 (zh)
MX (1) MXPA02004389A (zh)
NO (1) NO330947B1 (zh)
NZ (1) NZ518378A (zh)
PL (1) PL200273B1 (zh)
RU (1) RU2330666C2 (zh)
SK (1) SK287479B6 (zh)
TR (1) TR200200951T2 (zh)
WO (1) WO2001032183A2 (zh)
ZA (1) ZA200203394B (zh)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
EP1509207B1 (de) * 2002-05-31 2009-04-29 Desitin Arzneimittel GmbH Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
CA2494660A1 (en) * 2002-08-06 2004-02-19 Novartis Ag Use of carboxamides for the treatment of tinnitus
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
ATE446759T1 (de) * 2003-09-03 2009-11-15 Novartis Pharma Gmbh Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden
PE20060124A1 (es) * 2004-03-22 2006-03-07 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
WO2006046105A1 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Oxcarbazepine dosage forms
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
US20090143360A1 (en) * 2005-07-08 2009-06-04 Muhammed Safadi Oxcarbazepine Formulation
WO2007029093A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of oxcarbazepine
EP1815849A1 (en) * 2006-01-31 2007-08-08 Teva Pharmaceutical Industries Ltd Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
CA2634879A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of oxcarbazepine and methods for its preparation
US7722898B2 (en) * 2006-04-26 2010-05-25 Supernus Pharmaceuticals, Inc. Modified-release preparations containing oxcarbazepine and derivatives thereof
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
ES2559838T3 (es) 2007-03-16 2016-02-16 Concert Pharmaceuticals, Inc. Inhibidores de proteína de transferencia de ésteres de colesterol
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
JP2010524972A (ja) * 2007-04-19 2010-07-22 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化したモルホリニル化合物
ES2401914T3 (es) 2007-04-25 2013-04-25 Concert Pharmaceuticals Inc. Análogos de Cilostazol
US7608737B2 (en) 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
MX341177B (es) 2007-05-01 2016-08-10 Concert Pharmaceuticals Inc Compuestos de morfina.
PT2345653E (pt) 2007-05-01 2013-04-01 Concert Pharmaceuticals Inc Compostos de morfinano
HUE063526T2 (hu) 2007-05-01 2024-01-28 Concert Pharmaceuticals Ind Inc Morfinvegyületek
ES2356334T3 (es) 2007-06-12 2011-04-07 Concert Pharmaceuticals, Inc. Derivados de azapéptidos como inhibidores de la proteasa vih.
US8410124B2 (en) * 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
BRPI0908107A2 (pt) 2008-02-29 2019-09-24 Concert Pharmaceuticals Inc composto derivado de xantina substituída, composição farmacêutica que compreende esse composto, métodos de tratamento de uma enfermidade ou condição em um paciente com necessidade do mesmo, método de tratamento de enfermidade crônica dos rins, do fígado, relacionada com diabetes e de claudicação intermitente
WO2009146310A1 (en) * 2008-05-28 2009-12-03 Concert Pharmaceuticals Inc. Deuterated tizanidine
US20100221221A1 (en) * 2008-08-12 2010-09-02 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
AU2009293123B2 (en) 2008-09-19 2013-12-19 Concert Pharmaceuticals Inc. Morphinan compounds
HUE028956T2 (en) 2008-10-30 2017-01-30 Concert Pharmaceuticals Inc A combination of morphine compounds and an antidepressant for the treatment of pseudobulbar effects
EP2364151A1 (en) 2008-10-30 2011-09-14 Concert Pharmaceuticals Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
AU2009311645C1 (en) 2008-11-04 2014-10-02 Acer Therapeutics Inc. CXCR4 receptor compounds
US20110313004A1 (en) 2008-12-04 2011-12-22 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
US8501738B2 (en) 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
EP2536696A1 (en) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
EP2566494B1 (en) 2010-02-26 2017-11-29 Acer Therapeutics, Inc. Cxcr4 receptor compounds
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8513434B2 (en) 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US20120208837A1 (en) 2010-09-13 2012-08-16 Roger Tung Substituted azaindoles
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
CA2828251A1 (en) 2011-02-25 2012-08-30 Concert Pharmaceuticals, Inc. 2-amino-naphthyridine derivatives
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US20140128469A1 (en) 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
PT3235812T (pt) 2011-05-18 2019-12-09 Vertex Pharmaceuticals Europe Ltd Derivados deuterados de ivacaftor
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US20150011466A1 (en) 2012-01-09 2015-01-08 Anchor Therapeutics, Inc. APJ Receptor Compounds
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US9328113B2 (en) 2012-04-13 2016-05-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
EA201492287A1 (ru) 2012-06-15 2015-07-30 Консерт Фармасьютикалс, Инк. Дейтерированные производные руксолитиниба
US10017445B2 (en) 2012-07-12 2018-07-10 Concert Pharmaceuticals, Inc. Deuterated idebenone
EP3492472A1 (en) 2012-08-17 2019-06-05 Concert Pharmaceuticals Inc. Deuterated baricitinib with improved metabolic stability as jak1 and jak2 kinase inhibitor for treating e.g. rheumatoid arthritis
MY178621A (en) 2012-11-19 2020-10-19 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
WO2014100431A1 (en) 2012-12-20 2014-06-26 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
EP3470070B1 (en) 2012-12-21 2021-04-28 Mayo Foundation for Medical Education and Research Methods and materials for treating calcific aortic valve stenosis
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EA201892726A1 (ru) 2013-03-15 2019-04-30 Консерт Фармасьютикалс, Инк. Дейтерированный палбоциклиб
WO2014150043A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015010045A1 (en) 2013-07-18 2015-01-22 Anchor Therapeutics, Inc. Apj receptor compounds
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
WO2015063670A1 (en) * 2013-10-30 2015-05-07 Wockhardt Limited Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
CN106459056A (zh) 2014-02-10 2017-02-22 康塞特医药品公司 经取代的三唑苯二氮卓
EP3131554A1 (en) 2014-04-18 2017-02-22 Concert Pharmaceuticals Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
AU2015269247B2 (en) 2014-06-06 2019-10-24 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof
EP4180041A1 (en) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
WO2016144830A1 (en) 2015-03-06 2016-09-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
CA2981495C (en) 2015-03-31 2023-09-26 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
CA2994169A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
WO2017053455A1 (en) 2015-09-21 2017-03-30 Concert Pharmaceuticals, Inc. Administration of deuterated cftr potentiators
WO2017087795A1 (en) 2015-11-19 2017-05-26 Concert Pharmaceuticals, Inc. Deuterated epi-743
JP2019501899A (ja) 2015-12-09 2019-01-24 リサーチ トライアングル インスティテュート 改良アペリンレセプター（ａｐｊ）アゴニストおよびその使用
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
KR20190003711A (ko) 2016-05-04 2019-01-09 콘서트 파마슈티컬즈, 인크. 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
PT3478664T (pt) 2016-07-04 2020-12-28 Avanir Pharmaceuticals Inc Métodos para a síntese de dextrometorfano deuterado
KR102511953B1 (ko) 2016-08-01 2023-03-20 더 브리검 앤드 우먼즈 하스피털, 인크. 단백질 및 펩티드 전달용 입자
EP3589659A4 (en) 2017-02-28 2021-03-24 Mayo Foundation for Medical Education and Research CANCER TREATMENT COMPOUNDS AND METHODS
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
ES2928723T3 (es) 2017-05-19 2022-11-22 Superb Wisdom Ltd Derivados de Resiquimod
CN111491629A (zh) 2017-11-22 2020-08-04 康塞特医药品公司 D-丝氨酸的氘化类似物及其用途
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
AU2021372512A1 (en) 2020-10-28 2023-06-22 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
JP2024532765A (ja) 2021-08-12 2024-09-10 サン ファーマシューティカル インダストリーズ，インコーポレイテッド Ｊａｋ阻害剤のプロドラッグを用いたｊａｋ阻害応答性障害の治療
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20020022056A1 (en) * 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets

Also Published As

Publication number Publication date
ATE401892T1 (de) 2008-08-15
KR20020049004A (ko) 2002-06-24
PL366314A1 (en) 2005-01-24
JP2003514780A (ja) 2003-04-22
GB9925962D0 (en) 1999-12-29
ES2311001T3 (es) 2009-02-01
HU227685B1 (en) 2011-11-28
HK1050839A1 (en) 2003-07-11
EP1242091A2 (en) 2002-09-25
DE60039629D1 (de) 2008-09-04
PL200273B1 (pl) 2008-12-31
US20070037792A1 (en) 2007-02-15
TR200200951T2 (tr) 2003-01-21
NO20022058L (no) 2002-06-27
SK5842002A3 (en) 2002-08-06
ZA200203394B (en) 2003-07-29
AU777705B2 (en) 2004-10-28
IL205504A0 (en) 2011-07-31
WO2001032183A3 (en) 2002-07-04
HUP0203556A2 (hu) 2003-02-28
CN1407894A (zh) 2003-04-02
JP2012211202A (ja) 2012-11-01
IL149147A (en) 2010-11-30
RU2002113752A (ru) 2004-01-10
BR0015188A (pt) 2002-11-05
WO2001032183A2 (en) 2001-05-10
NZ518378A (en) 2004-10-29
RU2330666C2 (ru) 2008-08-10
HUP0203556A3 (en) 2004-03-01
CA2388609A1 (en) 2001-05-10
MXPA02004389A (es) 2002-09-02
NO20022058D0 (no) 2002-04-30
NO330947B1 (no) 2011-08-22
SK287479B6 (sk) 2010-11-08
JP2007224041A (ja) 2007-09-06
CA2388609C (en) 2011-01-04
US20060079502A1 (en) 2006-04-13
AU1997801A (en) 2001-05-14
KR100493836B1 (ko) 2005-06-08
CZ302847B6 (cs) 2011-12-14
EP1242091B1 (en) 2008-07-23
HK1050839B (zh) 2009-01-30
US20090252793A1 (en) 2009-10-08
CZ20021529A3 (cs) 2002-08-14

Similar Documents

Publication Publication Date Title
IL149147A0 (en) Use of oxcarbazepine for the manufacture of oral dosage form medicament
HK1047231A1 (en) Oral pharmaceutical forms of administration with adelayed action with tramadol
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
HUP0101293A2 (hu) AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása
IL205262A (en) Use of Risderdone Acid or its Pharmaceutical Salt to produce oral medication once a month for the prevention and treatment of osteoporosis
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
NZ595941A (en) Treatment of neurodegeneration and neuroinflammation
MXPA03007712A (es) Sales farmaceuticas.
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
WO2000078294A3 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
HUP0203303A3 (en) Compositions for administering taxanes orally to human patients
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
DE602004016963D1 (en) Therapeutisches system mit amoxicillin und clavulansäure
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
TNSN06072A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
IL146032A0 (en) Use of n-acetylcysteine for the preparation of a medicament suitable for intravenous administration to prevent oxidative stress in dialysed patients
HUP0400495A3 (en) Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
MXPA03010919A (es) Uso de acetil l-carnitina para preparacion de medicamento para terapia preventiva del dolor.
AU2001295884A1 (en) Dispenser for endermic administration of drug
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
TW200515912A (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep